Drug – bio-affecting and body treating compositions – Preparations characterized by special physical form – Tablets – lozenges – or pills
Reexamination Certificate
2002-08-19
2003-12-16
Page, Thurman K. (Department: 1616)
Drug, bio-affecting and body treating compositions
Preparations characterized by special physical form
Tablets, lozenges, or pills
C424S464000, C424S682000, C424S686000, C424S687000, C424S688000, C424S689000, C424S690000, C424S692000, C424S715000, C424S716000, C424S717000, C514S400000
Reexamination Certificate
active
06663892
ABSTRACT:
FIELD OF THE INVENTION
This invention relates to pharmaceutical dosage forms for the treatment of gastric disorders, and more particularly to multiple layer or multiple portion solid oral dosage forms comprising a histamine H
2
-receptor antagonist and an antacid.
BACKGROUND OF THE INVENTION
Gastrointestinal disorders such as acid indigestion, heartburn and gastritis are commonly treated with a histamine H
2
-receptor antagonist such as cimetidine, ranitidine, nizetidine and famotidine. Histamine H
2
-receptor antagonists reduce acid secretion by acting directly on the acid-secreting parietal cells located within the gastric gland of the stomach wall.
Antacids such as sodium bicarbonate, calcium carbonate, aluminum hydroxide and magnesium hydroxide are also commonly employed in the treatment of a large variety of nonspecific gastrointestinal symptoms. Antacids react with hydrochloric acid to form salt and water, thereby neutralizing gastric acid and raising gastric pH.
It has also been known to combine a histamine H
2
-receptor antagonist and an antacid in a single solid dosage form in order to provide immediate relief of pain and discomfort by neutralization of gastric acid with the antacid and independent inhibition of acid secretion with the histamine H
2
-receptor antagonist. However, it is well known that when histamine H
2
-receptor antagonists are co-administered with antacids, a substantial reduction in plasma bioavailability of the histamine H
2
-receptor antagonist is frequently observed. Accordingly, combinations of a histamine H
2
-receptor and an antacid have been contraindicated.
U.S. Pat. Nos. 5,629,026 and 5,656,652 state that absorption of the histamine H
2
-receptor antagonist of a solid dosage form containing a histamine H
2
-receptor antagonist and an antacid may be enhanced by optimally buffering the composition to confer a pH substantially equal to that of the pKa of the histamine H
2
-receptor antagonist. These patents disclose tablet formulations prepared by blending antacid granules and a histamine H
2
-receptor antagonist, along with conventional tableting aids, fillers and palatability aids, and tableting on a conventional machine. These patents do not suggest any interaction between the antacid and the histamine H
2
-receptor antagonist, and do not suggest any need for separating the antacid from the histamine H
2
-receptor antagonist.
It has been determined that unless special precautions are taken, the histamine H
2
-receptor antagonist will degrade in the presence of an antacid. U.S. Pat. No. 5,817,340 discloses that degradation of the histamine H
2
-receptor antagonist can be prevented by interposing a film-forming polymer barrier between the histamine H
2
-receptor antagonist and the antacid to prevent the therapeutic ingredients from contacting each other. A first of the disclosed embodiments is a tri-layer tablet which includes a first layer containing an antacid, a second layer containing a histamine H
2
-receptor antagonist, and a barrier layer interposed between the first and second layers. The barrier layer is a film or diaphragm or membrane composed of plastic material which prevents migration of the antacid from the first layer to the second layer, and prevents migration of the histamine H
2
-receptor antagonist from the second layer to the first layer. An alternative embodiment comprises a core containing a first active ingredient (e.g., the antacid), a polymer barrier coated over the core, and a shell formed over the polymer coated core and containing a second active ingredient (e.g., the histamine H
2
-receptor antagonist). In another embodiment, granules comprising one of the active ingredients (e.g., the histamine H
2
-receptor antagonist) are coated with a polymer barrier, and the coated granules are then mixed with the second active ingredient (e.g., the antacid), and pressed into tablets.
Thus, the known orally administrable solid dosage forms containing both an antacid and a histamine H
2
-receptor antagonist are either prepared without any regard for degradation of the histamine H
2
-receptor antagonist due to contact with the antacid, or are prepared with a barrier layer between a first portion containing the antacid, and a second portion containing the histamine H
2
-receptor antagonist.
SUMMARY OF THE INVENTION
This invention is directed to a solid orally administrable pharmaceutical dosage form comprising a first portion including a therapeutically effective amount of a histamine receptor antagonist, and a second portion immediately adjacent the first portion without an intervening barrier layer, the second portion including a therapeutically effective amount of an antacid. More specifically, it has been discovered that the histamine H
2
-receptor antagonist can be stabilized and protected from degradation induced by contact with the antacid by physically separating the actives into different portions without a discrete barrier layer interposed between the portions.
REFERENCES:
patent: 701438 (1902-06-01), Whyte
patent: 2888382 (1959-05-01), Pleyte et al.
patent: 3048526 (1962-08-01), Boswell
patent: 3125491 (1964-03-01), Elowe et al.
patent: 3358687 (1967-12-01), Miley et al.
patent: 3962107 (1976-06-01), Levin et al.
patent: 4664915 (1987-05-01), Simonian
patent: 4849218 (1989-07-01), Hess et al.
patent: 4869908 (1989-09-01), Kirschner et al.
patent: 5085865 (1992-02-01), Nayak
patent: 5190760 (1993-03-01), Baker
patent: 5229137 (1993-07-01), Wolfe
patent: 5571519 (1996-11-01), Synodis et al.
patent: 5629026 (1997-05-01), Davis
patent: 5656652 (1997-08-01), Davis
patent: 5681582 (1997-10-01), Gilis et al.
patent: 5736158 (1998-04-01), Quast
patent: 5817340 (1998-10-01), Roche et al.
patent: 6039974 (2000-03-01), MacLaren et al.
patent: 6086919 (2000-07-01), Bauer et al.
patent: 6183776 (2001-02-01), Depui et al.
patent: 6254886 (2001-07-01), Fusca et al.
patent: 6319519 (2001-11-01), Woolfe et al.
George Konata M.
L. Perrigo Company
Page Thurman K.
Price Heneveld Cooper DeWitt & Litton
LandOfFree
Multiple portion tablet does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Multiple portion tablet, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Multiple portion tablet will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3104954